Regional Variation of AKI in COVID-19 [COVID-19]
Research type
Research Study
Full title
Regional Variation of Acute Kidney Injury in COVID-19
IRAS ID
287831
Contact name
Nitin Kolhe
Contact email
Sponsor organisation
University Hospitals of Derby and Burton NHS Trust
Clinicaltrials.gov Identifier
N/A,
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality and has affected\nsome regions disproportionately. In England, London and West Midlands were overwhelmed in the early period of pandemic with increased in hospitalizations for pneumonia with multiorgan disease. One of the most serious complication of COVID-19 has been kidney involvement, in the form of acute kidney injury and the incidence of this has ranged between 5% to 57%. The medical fraternity rapidly learnt lessons in the first wave of the pandemic, whether it was with regards to use of continuous positive pressure ventilation in case of respiratory distress to the use of regional anticoagulation in acute kidney injury (AKI) needing continuous renal replacement therapy (CRRT). There was no effective treatment available at the start of the pandemic and this resulted in death rate rising sharply in England as well as many other countries. It has now become evident that there has been considerable variation in mortality in individual hospitals and there is urgent need to understand this unwanted variation. As the country tries to recover from the pandemic, it becomes more important to learn lessons with regards to its strategy of tackling the disease and its complication like AKI. This learning, can then be applied to a possible second spike of COVID-19 and prevent catastrophic consequences to the health and the economy. To address this need for learning, we will combine national database of hospital admissions and discharge with critical care dataset and census data from office of national statistic (ONS) over a period of four months of the pandemic to determine the regional incidence and case fatality of patients with COVID-19 disease and AKI in England. We will also explore various determinants of mortality in both COVID-19 and AKI in COVID-19.\n
REC name
N/A
REC reference
N/A